Teva to halt Phase II MSA therapy trial after futility analysis
Teva Pharmaceuticals has announced plans to halt a Phase II clinical trial evaluating emrusolmin (TEV-'286) to treat adults with multiple…
All articles by Srivani Venna
Srivani Venna
-
-
Bavarian Nordic secures four-year UK vaccine supply deal
Bavarian Nordic has secured a four-year contract from the UK Government to supply its MVA-BN vaccine, used for the prevention…
-
Zhimeng Biopharma concludes enrolment in ALS trial of CB03-154
Shanghai Zhimeng Biopharma has completed patient enrolment in the pivotal Phase II/III clinical trial of its investigational potassium-channel opener, CB03-154,…
-
Inovio’s Voceryq receives FDA accelerated approval for RRP
Inovio has secured accelerated approval from the US Food and Drug Administration (FDA) for Voceryq to minimise the frequency of…
-
Daiichi Sankyo, MSD withdraw cancer drug application
Daiichi Sankyo and Merck & Co (MSD) have voluntarily withdrawn their biologics license application (BLA) for ifinatamab deruxtecan, aimed at…
-
Innovent expands Phase III MarsLight-11 trial to non-squamous NSCLC
Innovent Biologics has announced an expansion of its global Phase III MarsLight-11 trial evaluating IBI363, also known as TAK-928, to…
-
Orum to begin Phase I trial of ORM-1153 after FDA clearance
The US Food and Drug Administration (FDA) has approved Orum Therapeutics' investigational new drug (IND) application for ORM-1153, a new…
-
Johnson & Johnson’s multiple myeloma treatment secures EC approval
The European Commission (EC) has approved an extended use of Johnson & Johnson's Tecvayli (teclistamab), along with daratumumab, to treat…
-
First patient dosed with DISP-10 in Dispatch Bio’s cancer trial
Dispatch Bio has dosed the first participant in a Phase I clinical trial aimed at evaluating the efficacy and safety…
-
Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments
Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases. These…